Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Akalin, Altuna Dr. (1) Berruezo Llacuna, Maria (1) Daniel, Peter Prof. Dr. (1) Di Virgilio, Michela Prof. Dr. (1) Driesner, Madlen (1) Graf, Robin Dr. (2) Höpken, Uta Elisabeth PD Dr. (1) Keller, Lisa (1) Keller, Ulrich Dr. med. (2) Kocks, Christine Dr. (1) Landthaler, Markus Prof. Dr. (1) Leutz, Achim Prof. Dr. (1) Lusatis, Simone (1) Mertins, Philipp Dr. (1) Pezzutto, Antonio Prof. Dr. (1) Popp, Oliver Dr. (1) Prigione, Alessandro Prof. Dr. (1) Rajewsky, Klaus Prof. Dr. (1) Rehm, Armin Dr. (1) Selbach, Matthias Prof. Dr. (9) Wollert-Wulf, Brigitte (2) Zauber, Henrik Dr. (1) (-) Janz, Martin Dr. (10) (-) Mathas, Stephan Dr. (9) Bioinformatics and Omics Data Science (1) (-) Biologie maligner Lymphome (15) Entwicklung Mechanismus-basierter Krebstherapien (2) Genetik und Genomik von Herz- Kreislauferkrankungen (1) Genomdiversifikation & Integrität (1) Mikroumgebung als Regulator bei Autoimmunität und Krebs (1) Molekulare Immunologie und Gentherapie (2) Proteomforschung und molekulare Mechanismen bei neurodegenerativen Erkrankungen (1) Translationale Tumorimmunologie (1) 1999 (2) 2000 (2) 2001 (1) 2002 (6) 2003 (3) 2004 (3) 2005 (3) (-) 2006 (5) (-) 2007 (4) 2008 (4) 2009 (4) 2010 (3) 2011 (4) 2012 (2) 2013 (3) 2014 (3) 2015 (5) 2016 (3) 2017 (5) 2018 (1) 2019 (2) (-) 2020 (6) 2021 (3) 2022 (7) 2023 (10) 2024 (2) 15 Ergebnisse: Active Filter: Janz, Martin Dr.Mathas, Stephan Dr.Biologie maligner Lymphome200620072020 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. April 2007 / Leukemia Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells M. Janz T. Stuehmer L.T. Vassilev R.C. Bargou 15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou 01. April 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel 01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken 15. Mai 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas 01. Oktober 2007 / Hematol Oncol Clin North Am The pathogenesis of classical Hodgkin's lymphoma: a model for B-cell plasticity S. Mathas 01. Juli 2006 / Blood Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma J.I. Martin-Subero I. Wlodarska C. Bastard J.M. Picquenot J. Hoeppner M. Giefing W. Klapper R. Siebert S. Mathas S. Joos H. Stein B. Doerken 01. März 2007 / Hum Immunol Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib M. Subklewe K. Sebelin-Wulf C. Beier A. Lietz S. Mathas B. Doerken A. Pezzutto 01. Mai 2007 / Br J Haematol Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis A. Lietz M. Janz M. Sigvardsson F. Jundt B. Doerken S. Mathas 01. Oktober 2020 / Invest New Drugs Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma F. Kroschinsky J.M. Middeke M. Janz G. Lenz M. Witzens-Harig R. Bouabdallah P. La Rosée A. Viardot G. Salles S.J. Kim T.M. Kim O. Ottmann J. Chromik A.M. Quinson U. von Wangenheim U. Burkard A. Berk N. Schmitz Seitennummerierung Aktuelle Seite 1 Seite 2 Nächste Seite Next › Letzte Seite Last »
01. April 2007 / Leukemia Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells M. Janz T. Stuehmer L.T. Vassilev R.C. Bargou
15. März 2006 / Blood Classical Hodgkin lymphoma is characterized by high constitutive expression of activating transcription factor 3 (ATF3) which promotes viability of Hodgkin/Reed-Sternberg cells M. Janz M. Hummel M. Truss B. Wollert-Wulf S. Mathas K. Joehrens C. Hagemeier K. Bommert H. Stein B. Doerken R.C. Bargou
01. April 2006 / Cell Death Differ Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma I. Sturm C. Stephan B. Gillissen R. Siebert M. Janz S. Radetzki K. Jung S. Loening B. Doerken P.T. Daniel
01. Februar 2006 / Nat Immunol Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma S. Mathas M. Janz F. Hummel M. Hummel B. Wollert-Wulf S. Lusatis I. Anagnostopoulos A. Lietz M. Sigvardsson F. Jundt K. Joehrens K. Bommert H. Stein B. Doerken
15. Mai 2006 / Cell Cycle Reprogramming of B lymphoid cells in human lymphoma pathogenesis M. Janz B. Doerken S. Mathas
01. Oktober 2007 / Hematol Oncol Clin North Am The pathogenesis of classical Hodgkin's lymphoma: a model for B-cell plasticity S. Mathas
01. Juli 2006 / Blood Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma J.I. Martin-Subero I. Wlodarska C. Bastard J.M. Picquenot J. Hoeppner M. Giefing W. Klapper R. Siebert S. Mathas S. Joos H. Stein B. Doerken
01. März 2007 / Hum Immunol Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib M. Subklewe K. Sebelin-Wulf C. Beier A. Lietz S. Mathas B. Doerken A. Pezzutto
01. Mai 2007 / Br J Haematol Loss of bHLH transcription factor E2A activity in primary effusion lymphoma confers resistance to apoptosis A. Lietz M. Janz M. Sigvardsson F. Jundt B. Doerken S. Mathas
01. Oktober 2020 / Invest New Drugs Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma F. Kroschinsky J.M. Middeke M. Janz G. Lenz M. Witzens-Harig R. Bouabdallah P. La Rosée A. Viardot G. Salles S.J. Kim T.M. Kim O. Ottmann J. Chromik A.M. Quinson U. von Wangenheim U. Burkard A. Berk N. Schmitz